SYPHARMA is a contract manufacturer based in Victoria, Australia that specializes in the production of both sterile and non-sterile biopharmaceutical products. As a TGA licensed manufacturer with over 15 years of experience in Aseptic Fill and Finish, SYPHARMA has established a solid reputation for delivering exceptional services and products to clients worldwide, not only as…

Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines.   Establishment of the first end-to-end Australian capability for product development and commercial scale production of mRNA, DNA and recombinant vaccines By bringing together the technology, product development, GMP manufacturing, clinical and…

COVID-19 vaccine developed by Vaxine Pty Ltd is the first Australian vaccine to reach final Phase 2 and 3 clinical trials Australian-developed COVAX-19 vaccine made from a synthetic spike protein combined with a unique sugar-based adjuvant turbocharger, has reached a major milestone with recruitment completed for the pivotal Phase 3 trial being conducted in the…

By Emma Koehn August 9, 2020 — 2.54pm | The Sydney Morning Herald   An Australian startup racing to develop a successful coronavirus vaccine has urged the federal government to ensure small firms are given development deals alongside pharmaceutical giants. Of more than 160 vaccine candidates around the world, the tie-up between global biotech CSL and the University…

“Everyone who prepares is one less person who panics in a pandemic” As Sypharma continues to closely monitor the CoVID-19 Pandemic, our primary concern is the health and safety of our staff, customers and the community. We will continue to deliver our products and we will endeavor to maintain our supply chain at this critical…

Around the world, pharmaceutical manufacturers and researchers’ objectives remain the same. To protect the safety of our community and to supply essential medicines for those who need them. This is our unique responsibility as an industry. Sypharma is honoured to announce that we have collaborated with the University of Queensland’s Rapid Response Vaccine Pipeline Program,…

July 10, 2020 Sypharma Partners with Vaxine — COVAX-19 Vaccine Candidate Enters Phase 1 Human Trials   Merck supports Vaxine’s production of Advax, through its manufacturing partner Sypharma, with process development expertise and services Sypharma to fill and finish COVAX-19 vaccine candidate and manufacture AdVax Adjuvant for Covid-19   Melbourne, Australia, July 10, 2020 –…

Around the world, pharmaceutical manufacturers and researchers’ objectives remain the same. To protect the safety of our community and to supply essential medicines for those who need them. This is our unique responsibility as an industry. Sypharma is honoured to announce that we have collaborated with Vaxine Pty Ltd to manufacture a first in human…